Sargramostim
- Generic Name
- Sargramostim
- Brand Names
- Leukine
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 123774-72-1
- Unique Ingredient Identifier
- 5TAA004E22
- Background
Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.
- Indication
For the treatment of cancer and bone marrow transplant
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Hematopoietic Subsyndrome of Acute Radiation Syndrome, Hodgkin's Lymphoma, Neutropenia, Non-Hodgkin's Lymphoma (NHL), Severe Infection
- Associated Therapies
- Allogenic bone marrow transplantation therapy, Autologous bone marrow transplantation therapy, Autologous peripheral haematopoietic stem cell transplant
Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma
- Conditions
- Interventions
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2018-05-03
- Lead Sponsor
- John P. Fruehauf
- Target Recruit Count
- 52
- Registration Number
- NCT00256282
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center, Orange, California, United States
Randomized Phase III Trial of Leukine® vs Neupogen® in Patients Receiving Cisplatin & Gemcitabine for Urothelial Cancer
- Conditions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2012-05-23
- Lead Sponsor
- University of Kentucky
- Target Recruit Count
- 100
- Registration Number
- NCT00237575
- Locations
- 🇺🇸
University of Louisville, Louisville, Kentucky, United States
🇺🇸University of Nebraska, Omaha, Nebraska, United States
🇺🇸New York Medical College, Hawthorne, New York, United States
Randomized Phase 2 Trial of Pre-chemotherapy Leukine vs. Leukine-Dexamethasone in Combination With Gemzar & 5-FU in Patients With Metastatic Renal Cell Carcinoma
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2015-06-18
- Lead Sponsor
- University of Kentucky
- Registration Number
- NCT00176280
Vaccine and Antibody Treatment of Prostate Cancer
- Conditions
- First Posted Date
- 2005-06-13
- Last Posted Date
- 2019-12-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00113984
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-08-05
- Last Posted Date
- 2014-03-31
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT00088933
- Locations
- 🇺🇸
Lombardi Comprehensive Cancer Center at Georgetown University, Washington, District of Columbia, United States
Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 87
- Registration Number
- NCT00005987
- Locations
- 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1449
- Registration Number
- NCT00026312
- Locations
- 🇺🇸
Rady Children's Hospital - San Diego, San Diego, California, United States
🇺🇸UCSF Medical Center-Parnassus, San Francisco, California, United States
🇺🇸UCSF Medical Center-Mission Bay, San Francisco, California, United States
Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-12-07
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 58
- Registration Number
- NCT00005601
- Locations
- 🇺🇸
CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States
🇺🇸CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States
🇺🇸CCOP - Cedar Rapids Oncology Project, Cedar Rapids, Iowa, United States
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-07-19
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 4
- Registration Number
- NCT00006747
- Locations
- 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸University of Massachusetts Memorial Medical Center - University Campus, Worcester, Massachusetts, United States
🇺🇸University of Illinois at Chicago, Chicago, Illinois, United States
A Phase I/II Pilot Study of Simultaneously Administered Rhu GM-CSF ( CHO Cell ) and Azidothymidine ( AZT ) in Patients With Severe HIV Infection and Leukopenia: Pharmacokinetics and Feasibility
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Sandoz
- Registration Number
- NCT00002006
- Locations
- 🇺🇸
Natl Cancer Institute, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.